logo
Plus   Neg
Share
Email

Array BioPharma Announces Results Of Phase 3 COLUMBUS Trial

Array BioPharma Inc. (ARRY) and Pierre Fabre announced results of the planned analysis of overall survival from the pivotal Phase 3 COLUMBUS trial in patients with BRAF-mutant melanoma.

Treatment with the combination of encorafenib 450 mg daily and binimetinib 45 mg twice daily (COMBO450) reduced the risk of death compared to treatment with vemurafenib 960 mg daily [hazard ratio (HR) of 0.61, [95% CI 0.47, 0.79, p <0.001]. Median OS was 33.6 months for patients treated with COMBO450, compared to 16.9 months for patients treated with vemurafenib as a monotherapy.

At the time of the planned analysis comparing COMBO450 to vemurafenib monotherapy, a preliminary analysis of OS in patients treated with 300 mg encorafenib alone daily (ENCO300), demonstrated a median OS of 23.5 months.

The U.S. Food and Drug Administration is currently reviewing the New Drug Applications to support use of the combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2018 for both applications.

In addition, the European Medicines Agency (EMA), as well as the Swiss Medicines Agency (Swissmedic) and the Australian Therapeutic Goods Administration (TGA), is reviewing the Marketing Authorization Applications for encorafenib and binimetinib.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Luxury online marketplace Farfetch has filed for an initial public offering or IPO to list its shares in the U.S. Farfetch has filed a F-1 registration statement with the U.S. Securities and Exchange Commission. The London-based company plans to list its shares on the New York Stock Exchange under the ticker 'FTCH.' Media reports indicate that IPO could value the company at up to $5 billion. Apple Inc. has reportedly removed more than 25,000 illegal apps from its App Store in China after coming under intense criticism from Chinese state media for failing to ban illegal online content on its platform. According to various media reports, the iPhone maker removed these illegal apps as they sold fake lottery tickets and offered gambling services. Hundreds of Google employees signed a petition protesting the company's secret project to develop a censored version of its search engine for China. In a letter, posted by Buzzfeed and first reported by the New York Times, the employees said that work on the project and Google's return to China raises "urgent moral and ethical issues." Google is trying to keep a foothold in China.
Follow RTT